Get Started
Companies · Targets

Targets

Drug targets across the portfolio with competitive landscape

10
Targets
1
Multi-Asset
11
Total Assets
Parathyroid hormone
Emerging
ASND
QW_TransCon_PTH ASND · Preclinical
YORVIPATH_TransCon_PTH ASND · Approved
2 asset(s)
C-type natriuretic peptide
Single Asset
ASND
TransCon_CNP_navepegritide ASND · NDA and MAA Accepted
1 asset(s)
Interleukin-2
Single Asset
ASND
TransCon_IL-2_b_g ASND · Phase 2
1 asset(s)
Human growth hormone
Single Asset
ASND
SKYTROFA_TransCon_hGH ASND · Approved
1 asset(s)
PTH receptor
Single Asset
ASND
Palopegteriparatide_YORVIPATH_TransCon_PTH ASND · Approved
1 asset(s)
Growth hormone pathway
Single Asset
ASND
TransCon_hGH ASND · Phase 2
1 asset(s)
Fibroblast growth factor 23
Single Asset
ASND
TransCon_FGF-23_degrader ASND · Preclinical
1 asset(s)
GLP-1 receptor
Single Asset
ASND
TransCon_semaglutide ASND · Preclinical
1 asset(s)
C-type natriuretic peptide pathway
Single Asset
ASND
TransCon_CNP ASND · Phase 3
1 asset(s)
VEGF
Single Asset
ASND
TransCon_aVEGF_EYC-0305 ASND · Preclinical
1 asset(s)